Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2022 | An insight into time-limited therapy in CLL

In this video, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses time-limited therapy in chronic lymphocytic leukemia (CLL). Dr Kater first highlights the use of novel agents such as ibrutinib and idelalisib, and the disadvantages of continuous therapy, including side effects, cost of treatment, and resistance of CLL cells to these agents. Dr Kater then discusses some clinical trials, including the MURANO trial (NCT02005471), which have shown that combining different classes of drugs gives rise to the possibility of deep remission and re-treatment of patients when relapse occurs. To conclude, Dr Kater emphasizes the importance of investigating biological markers and making use of measurable residual disease (MRD) to tailor treatment approaches to each patient and the importance of further investigating this. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Disclosures

Research funding Abbvie, Gennetech, Janssen, AZ, BMS